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1.1. Hepatitis C 
1.1.1. Epidemiology 
Hepatitis C virus (HCV) infection is a global health problem. Approximately 170 mil-
lion people are chronically infected with HCV worldwide. About 4 million people are 
yearly newly infected with HCV. Chronic hepatitis C (CHC) is estimated to be the 
cause of death for more than 350 thousand people each year (Marinho and Barreira 
2013; Mohd Hanafiah et al. 2013). Due to a complex mechanism of persistence mainly 
in hepatocytes and a high genetic variability of HCV, no vaccine is available yet (Liang 
2013). 
Chronic HCV infection is responsible for 50% of liver cirrhosis and 25% of hepatocel-
lular carcinoma in Western countries (Yano et al. 1996; Fattovich et al. 1997; Hu und 
Tong 1999). In the USA the populations at high risk of developing CHC were intrave-
nous drug consumers or the people who have received blood transfusions until 1992 
(Denniston et al. 2014).
 
The prevalence of HCV varies in Europe, between 2% in Southern Europe to 0.5% in 
Northern Europe (Cornberg et al. 2011). It is estimated that in Germany, every year 
5000 people are newly infected with HCV, with a total number of approximately 350 
000 persons. In developed countries, the majority of the HCV infections are caused by 
the intravenous drug abuse, represented mostly by a younger population. In less devel-
oped countries, a disrespect to the hygienic aspects during medical procedures repre-
sents an important cause for new HCV infections (Hatzakis et al. 2013; Wantuck et al. 
2014). The HCV neonatal transmission risk is between 3 to 5 % from an HCV-positive 
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mother to her infant. This risk is positively correlated to the level of HCV-RNA copies 
in the mothers’ blood, HIV coinfection and invasive procedures (Floreani 2013). 
The populations at risk for the infection with HCV are represented by: intravenous drug 
consumers, blood transfusion receivers (risk had massively decreased after the introduc-
tion of HCV screening in 1990), sexual contacts with an intravenous drug user, people 
that have been stuck or cut with a bloody object, people that have piercings in ears or in 
other body parts, immunoglobulin injection receivers (Murphy et al. 2000). Other risks 
are represented by hemodialysis (massively decreased after HCV screening), organ 
transplantation, sexual or household contact with an HCV-positive patient or healthcare 
workers (Pereira et al. 1991; Geerlings et al. 1994; Stroffolini et al. 2001). 
1.1.2. Hepatitis C Virus 
HCV is a positive-sense, single-strand RNA virus belonging to the family of Flaviviri-
dae. HCV was discovered in 1989 as the causative agent for posttransfusion or non-A-
non-B hepatitis (Choo et al. 1989). Initially, HCV infection was diagnosed by the detec-
tion of anti-HCV specific antibodies using enzyme-linked immunosorbent assays (ELI-
SA); later-on the reverse transcription polymerase chain reaction (RT-PCR) became es-
tablished for the direct detection of viral genomes (Cha et al. 1991; Chien et al. 1992). 
Choo et al. identified the full nucleotide sequence of the HCV, using overlapping com-
plementary DNA clones (Choo et al. 1989). 
HCV has 7 genotypes (1 to 7) and approximately 100 subtypes (Scheel and Rice 2013). 
While HCV genotypes 1, 2 and 3 have a global distribution, the HCV genotype 4 and 5 
is spread mostly in Central and South Africa, genotype 6 in South East Asia, genotype 7 
in Central Africa (Magiorkinis et al. 2009; Scheel and Rice 2013). Genotype 1 is the 
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most common HCV genotype in Western countries and also in Germany (Scheel and 
Rice 2013). 
The HCV genome has a length of approximately 9.600 nucleotides (Choo et al. 1989). 
The internal ribosomal entry site (IRES) is located at the 5’ terminus and it is a highly 
conserved untranslated structure (Bartenschlager et al. 2011). The 3’ end of the HCV 
genome contains an untranslated conserved region (the poly U sequence) (Tanaka et al. 
1996) (Figure 1). As a result of the HCV genome translation a polyprotein is synthe-
sized. From this HCV polyprotein three structure (core, E1, E2) and seven non-structure 
proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B) are generated, mainly by sig-
nal peptidase and autocleavage procedures (Scheel and Rice 2013). 
 
Figure 1 (modified from Scheel and Rice 2013 with Nature Publishing Group authorization) HCV ge-
nome and polyprotein processing. The HCV RNA contains one long translated region (blue) flanked by 5′ 
and 3′ UTRs (red). IRES-mediated translation of the translated region leads to a polyprotein (bottom) that 
prepared into viral structure and non-structure proteins. The development of the core protein requires the 
cleavage of a C-terminal signal peptide (white triangle). The E1 structure protein is cleaved due to a cel-
lular signal peptidase. The sections E1, E2 and p7 are fragmented from the polyprotein (gray triangles) by 
the same cellular signal peptidase. The NS2-NS3 protease has a self-separation mechanism (red triangle). 
NS4A separates the other non-structural proteins (green triangle) (Scheel and Rice 2013). 
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HCV virions are incorporated into lipid virus particles, together with Apoprotein E, B 
and C (Agnello et al. 1999; Barth 2003). The structure of the lipidviro-particles has sim-
ilarities with the low density lipoprotein (LDL) and very low density lipoprotein 
(VLDL) (Thomssen et al. 1992; Monazahian et al. 1999). This aspect is considered as a 
characteristic mark of the HCV. At the hepatocytes membrane level, many receptors 
and proteins are involved in the entry of the virus into the cells, like: LDL-Receptor, 
glycosaminoglycans, Scavenger Receptor part B1(SRB1), Transpanin, CD81, Claudin-1 
(CLDN1) and occluding (OCLN) (Scheel and Rice 2013). The intrusion of the virion 
particles into the hepatocytes is made via clathrin-mediated endocytosis, followed by an 
acid pH-dependent fusion and uncoating process (Blanchard et al. 2006; Tscherne et al. 
2006). 
The HCV genome will be released into the cytoplasm, where it will be translated. The 
infection with HCV might also occur transcellularly from an infected to a non-infected 
hepatocyte (Timpe et al. 2008). 
The translation of the HCV genome takes place at the endoplasmatic reticulum level 
(Bartenschlager et al. 2004; Moradpour et al. 2007). This stage is initiated by the HCV 
IRES 5’ terminal end (Hoffman und Liu 2011). 
The HCV RNA replication takes place in the endoplasmatic reticulum-derived vesicles, 
which act as a membranous web (Romero-Brey et al. 2012). NS5B acts as RNA-
dependent RNA-polymerase and together with other non-structural proteins and factors 
like Cyclophilin A and micro RNA (miR-122) catalyzes the HCV replication in the 
membranous web (Lesburg et al. 1999; Gosert et al. 2003; Lohmann 2013). After the 
replication, the resulted HCV genomes could be translated, replicated or incorporated 
into HCV particles (Miyanari et al. 2007). 
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The HCV assembly and release is a process that is associated with the lipid metabolism 
of the host cell. In the proximity of endoplasmatic reticulum, the nucleocapside is as-
sembled, and E1, E2, P7, NS2 are attached to it (Lindenbach 2013). The nucleocapsid is 
transferred to the luminal lipid droplets following the VLDL pathway that will later 
form the lipid virus particles, which get enriched with Apo-B and Apo-E. The lipid vi-
rus particles follow then the cellular excretory pathways from Golgi (Gastaminza et al. 
2008; Bartenschlager et al. 2011; Counihan et al. 2011; Coller et al. 2012) (Figure 2). 
 
Figure 2 (modified from Scheel and Rice 2013 with Nature Publishing Group authorization) The HCV 
life cycle. Start of hepatocyte infection via interaction of extracellular HCV lipid virus particles (LVPs) 
(1) with cellular surface receptors (2). This procedure can also occur via cell-to-cell transmission. Fusion 
and uncoating of the HCV particles is pH-dependent and it is followed by translation and post-
translational processes resulting in the HCV polyprotein (3). The replication takes place in the membra-
nous web (4). HCV assembly and release follows the VLDL pathway, and LVPs are released from Golgi 
(Scheel and Rice 2013). 
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          1.1.3. Hepatitis C infection symptoms and associated complications 
Hepatitis C infection is usually asymptomatic. Flu-like symptoms appear only in 25% of 
the cases. An acute hepatitis C is not common, with about 80% becoming a chronic in-
fection (persistence of HCV RNA and elevated ALT more than six months).  
Patients with CHC infection have a higher risk of developing liver cirrhosis (20%), por-
tal hypertension complications, liver failure and hepatocellular carcinoma (annual inci-
dence 4-5% among the patients with CHC and liver cirrhosis) (El-Serag and Mason 
1999; Di Bisceglie et al. 2003; Chen und Morgan 2006; Thomas et al. 2010). 
In the USA, the annual costs of HCV therapy and HCV-infection associated complica-
tions are estimated at 5.5 billion $, most of them caused by the complications of chronic 
liver disease treatment and hepatocellular carcinoma treatments (Leigh et al. 2001). 
These facts set HCV therapy as an important player worldwide in the countries health 
budget. In the era of direct acting antivirals (DAA), the costs of CHC treatment are 
higher, but hopefully the new positive results in the elimination of the HCV will im-
prove the overall costs of CHC patients in the health budgets (Mechie et al. 2015). 
          1.1.4. Hepatitis C Therapy 
The therapy success is defined as a durable and sustained elimination of the virus at 24 
weeks after the therapy. The elimination of the HCV is represented by undetectable lev-
els of HCV-RNA utilizing a high sensitivity assay (limit of detection for HCV-RNA 12-
15 IU/ml). A sustained virological response (SVR) is defined as undetectable HCV-
RNA 24 weeks after the end of therapy and it defines a 99% of therapy success (Swain 
et al. 2010). A rapid virological response (RVR) is represented by an undetectable level 
of HCV-RNA in the first 4 weeks after initiation of therapy. A complete early virologi-
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cal response is represented by the absence of HCV-RNA from serum in the first 12 
weeks of the antiviral therapy. A breakthrough is represented by a 10 fold (1 log) or 
more rise of the HCV-RNA level under antiviral therapy or a new detection of HCV-





 week of the antiviral treatment or persistence of HCV-
RNA in serum until the 24
th
week.  
In 1986, the first steps in the therapy for HCV (formally non-A-non-B associated hepa-
titis) were made. At this time point, the only treatment option was Interferon-α (IFN-α) 
(Hoofnagle et al. 1986). Even after HCV discovery IFN-α remained the therapy of 
choice for CHC, but only with a SVR rate of approximately 20% (Di Bisceglie et al. 
1989; Causse et al. 1991). The mechanisms through which the IFN-α interacts with 
HCV replication are multiple. We could nominate here the suppression of the HCV 
translation, the degradation of the HCV-RNA, the activation of the immunological sys-
tem for the recognition of the HCV-infected cells and the prevention of HCV-infection 
in the susceptible hepatocytes (Mihm et al. 2003; Mihm et al. 2004; Meier et al. 2008). 
The most common side effects of the therapy with IFN- are: flue-like symptoms 
(headaches, muscle pain, fever), hematological disorders (neutropenia, thrombocytope-
nia), neuropsychiatric effects (depression, irritability, mood disorder) and thyroid dys-
functions (Schaefer et al. 2005; Maan et al. 2014). 
The next step in the CHC therapy was represented by the addition of RBV to the IFN-α 
therapy. RBV is a nucleotide analog with a large spectrum in the therapy of viral dis-
eases. RBV is used in the therapy of both RNA and DNA viruses (Patterson and Fer-
nandez-Larsson 1990). The clinical trials have proven that the combination of the two 
antiviral substances (IFN-α and RBV) had better SVR rate than IFN-α alone, becoming 
the standard therapy in the therapy of CHC (McHutchison et al. 1998; Reichard et al. 
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1998). With the combination of IFN-α and RBV a SVR rate of approximately 40% 
could be achieved in the cases of chronic HCV genotype 1 patients. Anemia and the ter-
atogenic effect of RBV are one of the most common side effects of the therapy with this 
agent (McHutchison et al. 2006). 
The next crucial development in the therapy of CHC was the introduction of Peg-IFN-α. 
With the attachment of the polyethylenglycol to the standard IFN-α, a much longer bio-
logical half-life was reached. For the combination of RBV and Peg-IFN-α, SVRs were 
reported between 45 to 80%, depending on the HCV genotype (Glue et al. 2000; Manns 
et al. 2001; Sulkowski et al. 2002). Another variant for the CHC therapy was the Peg-
IFN-λ1. Peg-IFN-λ1 had in studies similar results to the Peg-IFN-α but with lower inter-
feron specific side effects (Muir et al. 2010; Muir et al. 2014). 
For the CHC patients, who did not respond to the antiviral treatment, therapeutic possi-
bilities were limited to a re-exposure to the same category of therapeutics with modifi-
cation of the regime of applying. These re-treatment strategies were associated with 
higher rates of side effects and usually with lower SVR rate (Jensen et al. 2009; Poyn-
ard et al. 2009; Mechie et al. 2015). 
New therapeutic options have been recently introduced such as direct acting antiviral 
agents (DAAs) which specifically inactivate HCV enzymes like NS3/4A, NS5A or 
NS5B. In 2011 the first two DAAs have started a new era in the treatment of CHC pa-
tients. Boceprevir and Telaprevir are specific NS3/4A protease inhibitors of HCV and 
were approved, in combination with Peg-IFN-α and RBV for the therapy of CHC. The 
SVR rate was raised to approximately 80% due to the first DAAs. Recently, a variety of 
DAAs such as Sofosbuvir, Simeprevir, Daclatasvir etc. were approved for treatment of 
CHC. These agents are being used either in combination with Peg-IFN-α and/or RBV or 
as IFN-α-free regimes, and obtain significant better SVR rates than Peg-IFN-α and RBV 
9 
 
alone (Jacobson et al. 2013; Kowdley et al. 2013; Lawitz et al. 2013; Afdhal et al. 
2014a; Lawitz et al. 2014a; Sulkowski et al. 2014; Lawitz et al. 2014b). 
The new IFN-free therapy regimen with Ombitasvir, Paritaprevir, Ritonavir (Vie-
kirax®) and Dasabuvir (Exviera®) shows SVR rates of more than 95% with an ac-
ceptable side effect profile. Moreover, this therapy is also approved for patients that 
have received a liver transplantation (Hézode et al. 2015; Klibanov et al. 2015). 
The costs of the DAA based antiviral therapy are very high, for example a three months 
therapy costs for Sofosbuvir approximately 60,000€. These aspects represent an im-
portant limiting factor for the CHC therapy (Petta et al. 2014; Mechie et al. 2015). On 
the other side the approval studies were performed with highly selected patients. The 
limiting factor regarding the costs of the treatment regime is important due to the fact 
that the majority of the CHC patients is treated in developing countries. The new DAAs 
(Sofosbuvir, Ledispasvir, Daclatasvir or Semiprevir) are not everywhere accessible for 
the therapy. This is an important reason to select the patients, who could achieve an 
SVR with Peg-IFN and RBV, to offer an affordable CHC therapy for these patients and 
to avoid new side effects (Mechie et al. 2015). 
1.1.5. Predictors in the therapy of Hepatitis C 
In order to identify specific predictors of the SVR, several studies were conducted. The 
predictors, which were identified, are categorized in virus or host related factors (As-
selah et al. 2010; Khattab et al. 2010; Ramcharran et al. 2010; Amanzada et al. 2012b; 





          1.1.5.1. Virus-related predictors  
HCV genotype 1 is considered to have the lowest treatment response rate to Peg-IFN-α 
and RBV (≈55%) compared to the other HCV genotypes. Studies for genotype 2 and 3 
reported an SVR rate of about 80% (Asselah et al. 2010). 
Low pretreatment serum HCV-RNA levels (< 800 000 IU/mL) showed a positive pre-
dictive value for therapy outcome with Peg-IFN-α and RBV (Asselah et al. 2010). 
RVR is the most important predictive marker in the CHC therapy. Patients who 
achieved virus elimination at week 4 after the initiation of the therapy have showed 
higher SVR rates (Martinot-Peignoux et al. 2009). 
1.1.5.2. Host-related predictors  
Race (Afro-Americans have lower SVR rates compared to Caucasians and people from 
Asia and Japan have the best SVR rates) and age (higher age is associated with lower 
SVR rate) are two demographical factors that are associated with therapy outcome (As-
selah et al. 2010). 
Conditions of insulin resistance, obesity and cirrhosis have also a negative predictive 
value in the outcome of CHC therapy (Asselah 2006; Khattab et al. 2010). 
Drug abuse, alcohol consumes and coinfections with HIV or HBV are also associated 
with a lower SVR rate (Alberti 2009). 
  Host laboratory parameter such as: low γ-GT, high ALT activity, low pretreatment γ-
GT/ALT ratio, early anemia during therapy, high LDL and low HDL levels were signif-
icantly associated with therapy outcome (Mihm et al. 1996; Mihm et al. 1999; Gopal et 
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al. 2006; Shiffman et al. 2007; Economou et al. 2008; Harrison et al. 2010; Weich et al. 
2011; Amanzada et al. 2012a). 
In 2009, three genome-wide association studies identified polymorphisms in the neigh-
borhood of IFN-λ3 gene, on chromosome 19, to be highly associated with therapy suc-
cess in CHC patients infected with HCV genotype 1, who received an antiviral therapy 
consisting of Peg-IFN- and RBV (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 
2009). IFN-λ3 rs12979860 is the most investigated polymorphism of IFN-λ3 in the 
western world. The molecular and immunological mechanism between the IFN-λ3 and 
HCV is still unclear. In 2013 a dinucleotide polymorphism ss469415590 (TT/G) has 
been proven to create IFN-4 (G). The absence of IFN-λ4 (TT) has been shown to be 
a better genetic predictor than IFN-3 for the success of the therapy with Peg-IFN-α and 
RBV (Amanzada et al. 2013a; Bibert et al. 2013; Prokunina-Olsson et al. 2013). IFN-3 
polymorphism is recommended by The American Association for the Study of Liver 
Diseases, as an important predictive marker for the antiviral treatment with Peg-IFN- 
and RBV or in combination with DAA. Recently we could show that the CC genotype 
of IFN-λ3 rs12979860 has a predictive value also in the combination of Peg-IFN-α, 
RBV and a DAA (Mechie et al. 2014). However, the IFN-λ3 predictive value is smaller 
in the case of the triple therapy (Peg-INF-α, RBV and a DAA) than in the case of Peg-
IFN-α and RBV alone. The predictive value of IFN-λ3 is also variable between the 
DAAs (Mechie et al. 2014). Furthermore, in studies that investigated interferon-free 
based therapy regimens, the IFN-λ3 rs12979860 CC genotype was found to be correlat-





1.2. Vitamin B12          
1.2.1. Vitamin B12- physiology and pathophysiology  
Vitamin B12 is one of the water soluble vitamins, which is also named cobalamine. Hu-
mans are not capable to synthesize Vitamin B12 and its only source is represented by 
meat and dairy products. 
The Vitamin B12 chemical structure consists of a central cobalt in a tetra-pyrrole-ring 
(corrin-ring) (Figure 3). 
 
Figure 3. Chemical structure of Vitamin B12, modified after Degnan et al. with permission from Elsevier 
(Degnan et al. 2014). 
The recommended dietary intake for Vitamin B12 is for adults 2 µg/d and 2.6 µg/d for 
pregnant women. A normal diet provides a daily intake of approximately 5-7 µg. The 
Vitamin B12 reserves are estimated at 2 to 5 mg (Green and Kinsella 1995). A low con-
sumption of Vitamin B12 leads therefore to Vitamin B12 deficiency years after stopping 
an adequate alimentary intake of Vitamin B12. The excess of Vitamin B12 is mainly 
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eliminated through bile (part being reabsorbed by enterohepatic circulation) (Reizen-
stein 1959; Adams 1970; el Kholty et al. 1991). 
Vitamin B12 is liberated in the stomach from the binding protein by the low pH of the 
gastric acid. R-Protein, which is secreted by the saliva, binds to Vitamin B12 in the 
stomach to prevent degradation of Vitamin B12 due to the acid milieu. In the duodenum 
it comes in contact with an alkaline milieu and with the pancreatic enzyme that releases 
Vitamin B12 from R-protein. Vitamin B12 combines with Intrinsic Factor (IF), a protein 
that is secreted in the stomach by the parietal cells, creating the Vitamin-B12-IF-
complex. In the terminal ileum, the Vitamin-B12-IF-complex is recognized by the IF-
receptor and the absorption of Vitamin B12 takes place. Vitamin B12 is absorbed into the 
portal system and is transferred to Transcobalamin II (TCII). The TCII-Vitamin B12-
complex binds to a receptor and is transferred intracellular via endocytosis, where TCII 
undergoes a lysosom-associated degradation following the liberation of Vitamin B12 in-
to the cytoplasm (Tefferi and Pruthi 1994; Guyton and Hall 2006). 
Vitamin B12 is physiologically stored in the liver tissue. Vitamin B12 deficiency could 
appear in several liver diseases such as: cirrhosis, hepatocellular carcinoma, hepatitis 
and liver metastasis (Nicolas and Guéant 1994; Mechie et al. 2015). This could be ex-
plained by the impaired liver storage, consequent to the high release during hepatic cy-
tolysis or decreased clearance in the affected liver. 
Vitamin B12 is metabolically involved, especially in the DNA synthesis, a fact that it 
confers a key role in the cellular metabolism (Guyton and Hall 2006). 
Vitamin B12 deficiency is associated with hematological manifestations like macrocytic 
anemia, pernicious anemia or neurological manifestations (dementia, progressive weak-
ness, ataxia, paraesthesia) (Hemmer et al. 1998). 
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Vegan patients (intake deficiency), patients on which a total gastrectomy, stomach by-
pass or terminal ileum resection was performed (absorption deficiency), or with nitric 
oxide exposure (inactivation) are at risk to develop Vitamin B12 deficiency (Antony 
2003; Balcı et al. 2014). 
High levels of serum Vitamin B12 were described in a series of diseases like: hypereo-
sinophilic syndrome, myeloproliferative neoplasm, multiple myeloma (due to elevated 
TC levels of raised production of granulocytes and their precursors), liver diseases (cir-
rhosis, hepatitis, malignancies) due to impaired storage or decrease Vitamin B12 clear-
ance, renal failure, inflammatory diseases (rheumatoid arthritis, systemic lupus reuma-
toides) (Andres et al. 2013). 
1.2.2. Vitamin B12 and Hepatitis C Virus 
Several studies have proven, in vitro conditions, that Vitamin B12 inhibits HCV IRES-
dependent translation. It is supposed that the inhibition process is due to a direct interac-
tion between Vitamin B12 and HCV IRES RNA (Lott et al. 2001; Takyar et al. 2002). Li 
et al. demonstrated that HCV IRES domain IV (Figure 4) is responsible for the inhibito-




Figure 4. The Secondary structure of the HCV IRES, adapted from Honda et al. (Honda et al. 1996; Lott 
et al. 2001). © 2001National Academy of Sciences. 
 
The main element of the HCV IRES is domain III, which during translation is attached 
to the 40S ribosomal subunit. We know that Vitamin B12 allows the assembling of the 
translation complex between the 80S ribosomal subunit and HCV IRES, but seems to 
stop the translation process (Takyar et al. 2002). As the hepatocytes represent the natu-
ral reservoir for Vitamin B12, having high intracellular Vitamin B12 levels, the inhibition 
effect of Vitamin B12 on the HCV translation could be one of the mechanisms to which 
HCV became adapted causing chronic infection and very rare acute hepatitis (Li et al. 
2004). Due to the short half-life (few hours) of the HCV virions, HCV-RNA is a good 
parameter for the quantification of the HCV replication. Elevated serum Vitamin B12 
levels were shown to be associated with high viral load in CHC patients, a fact that sug-
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gests a biological significance and interaction between Vitamin B12 in HCV life cycle 
(Lott et al. 2001). Only one study suggested that serum Vitamin B12 levels are associat-
ed with end-of-treatment response in CHC patients (Rosenberg and Hagen 2011). An 
open-label pilot study demonstrated that supplementation of Vitamin B12 to the therapy 
with Peg-IFN-α and RBV increases the SVR rates in treatment naïve CHC patients 
(Rocco et al. 2013). 
1.3. Aim  
The aim of this study was (I) to determine the relation between serum Vitamin B12 lev-
els with regard to serum HCV-RNA, clinical and histological characteristics of CHC pa-
tients and (II) to evaluate its predictive value for treatment outcome in CHC patients 




2. MATERIALS AND METHODS 
2.1. Patients 
The demographical, laboratory and histological data from a total of 116 CHC genotype 
1-infected patients was analyzed in this study. All patients were from Germany, of Cau-
casian ethnicity and treated as out-patients in the Department of Gastroenterology at the 
University Medical Center Göttingen (UMG). CHC was regarded by the presence of 
HCV RNA in patients’ sera for at least six months, the presence of anti-HCV antibodies 
and biochemical and/or histological signs of liver inflammation. Liver biopsy samples 
were acquired using standard techniques, ultrasound guided biopsy or mini laparoscopy, 
as a part of a routine clinical evaluation (Mechie et al. 2015). After taking liver biopsy, 
liver samples were fixed in formalin and embedded in paraffin. The necroinflammatory 
activity was graded according to Desmet et al. (grading score 1-3).The staging is repre-
sented by the grade of fibrosis or cirrhosis and was graded according to Desmet et al.: 
no fibrosis (score 0), mild (score 1, periportal fibrous expansion), moderate (score 2, 
portal-portal septa), marked (score 3, bridging fibrosis/ portocentral septa), or cirrhosis 
(score 4) (Desmet et al. 1994). The histopathological evaluation was performed without 
knowledge of patient clinical and biochemical parameters at the Institute of Pathology 
UMG, http://www.pathologie-umg.de. 
All 116 patients with HCV genotype 1 received an antiviral combination therapy con-
sisting of Peg-IFN- and RBV. The patients were followed up during the therapy at the 
Department of Gastroenterology and Endocrinology, UMG (Mechie et al. 2015). 
Exclusion criteria comprised: active HBV infection, HIV coinfection, continued alcohol 
or intravenous drug abuse, or immunosuppressive medication. None of the patients in-
cluded in the present study had diseases that could be associated with high serum Vita-
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min B12 levels like myeloproliferative disorders, acute fulminate hepatitis, hypereosino-
philic syndrome or a renal failure (Mechie et al. 2015). 
In order to participate in the study, all patients gave written informed consent in accord-
ance with the ethical guidelines of the 1975 Declaration of Helsinki. The study was ini-
tially approved by the ethics committee of the University Medical Center with the num-
ber 4/8/93 with a subsequent amendment from 2010. This dissertation was approved 
with the reference number DOK_101_2014. 
Treatment was performed according to  standard therapy regimens at that time: with a 
combination of Peg-IFN-α2b in a dose of 1.5 µg/kg body weight and weight-based RBV 
(800 to 1400 mg per day) or a combination of 180 µg Peg-IFN-α2a with weight-based 
RBV (1000 or 1200 mg per day). Depending upon the presence of the side effects and 
viral dynamic, both the dose and duration of therapy were adjusted. Viral load was 
monitored monthly, and achievement of RVR or SVR was documented (Mechie et al. 
2015). 
2.2. Laboratory analysis  
The following laboratory analyses were performed using automated systems in the Cen-
tral Laboratory at the Department of Clinical Chemistry, UMG: aspartate aminotrans-
ferase (AST) activity, alanine aminotransferase (ALT) activity, -glutamyl-transferase 
(-GT) activity and baseline serum Vitamin B12 concentration (Mechie et al. 2015). 
Serologic parameters of viral hepatitis due to HBV or HCV infection (anti-HBs, anti-
HBc and anti-HBe antibodies, HBs antigen, anti-HCV antibodies) were determined in 




2.3. Isolation of genomic DNA and IFN-λ3 rs12979860 single nucleotide polymor-
phism (SNP) genotyping 
Isolation of genomic DNA and IFN-λ3 rs12979860 SNP genotyping were conducted as 
part of the Department’s Virologic and Molecular Diagnostics at UMG as described 
previously by Amanzada et al. 2012b. 
Peripheral blood mononuclear cells were taken as a source for the isolation of genomic 
DNA using the QIAamp DNA Mini Kit and following the manufacturer’s protocol (Qi-
agen). Absorbance was measured at 260 and 280 nm to determine concentration and pu-
rity of the isolated nucleic acids. In order to assess the integrity of genomic DNA, aga-
rose gel electrophoresis was applied. DNA extraction was performed with QIAamp 
DNA Blood Midi Kit from 2 mL serum when insufficient sanguine probes were availa-
ble (Amanzada et al. 2012b). 
Isolated DNA was amplified by real-time PCR using TaqMan Universal Master Mix 
(Applied Biosystems, Darmstadt, Germany). The primers used for IFN-λ3 rs12979860 
SNP genotyping were: forward, 5′-GCCTGTCGTGTACTGAACCA-3′ and reverse 5′-
GCGCGGAGTGCAATTCAAC-3′. Allelic discrimination of IFN-λ3 was performed 
with differentially fluorescent dye-labeled allele-specific minor groove binder probes 
for IFN-λ3 rs12979860 (VIC, 5′-TGGTTCGCGCCTTC-3′; FAM, 5′-
CTGGTTCACGCCTTC-3′). Reactions and analyses were performed with ABI prism 
StepOne plus (Applied Biosystems) according to the suppliers' instructions as described 





2.4. Detection and determination of serum HCV-specific RNA and HCV genotype 
The determination of the serum HCV-specific RNA and HCV genotype was performed 
by the Department’s Virologic and Molecular Diagnostic Unit as described previously 
by Amanzada et al. 2012b and by Mihm et al.1996. 
Serum HCV-specific RNA was determined utilizing a nested RT-PCR approach;  HCV 
genotypes were determined using a line-probe assay as described (Mihm et al. 1996; 
Amanzada et al. 2012b). 
Serum samples (140 µL) were used in order to extract the HCV RNA. To perform this 
process we have used the QIAamp Viral RNA Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturers' protocol. With the extracted HCV RNA a nested RT-PCR pro-
cedure was performed, using 2 tagged RT-PCR, as described by Mihm et al. 1996. To 
quantify the virus in human sera, an Abbott real-time HCV assay was used, with a de-
tection limit of 12 IU/mL (Amanzada et al. 2012b). 
In order to determine HCV genotypes, the Innolipa HCV II line probe assay (Innogenet-
ics, Ghent, Belgium) was applied, according to the manufacturer’s protocol as described 
previously by Amanzada et al. 2012b. 
2.5. Statistical analyses 
Logistic regression models were used to determine the association between serum Vit-
amin B12 levels and the continuous and dichotomous variables. The univariate and mul-
tivariate analyses were performed in R Program by A. D. Goralzcyk. In the first step a 
univariate analysis was performed for all variables. For the ones, which were found sig-
nificant in the univariate analysis (p< 0.05), a multivariate analysis was conducted. A 
backward selection, with a p-value > 0.10 for the elimination from the statistical model 
was applied in the multivariate analysis. Quartiles and interquartile range were used be-
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cause data regarding serum Vitamin B12 were found to be skewed. Spearman’s correla-
tion was used to determine the association between the continuous variables. By intro-
ducing different sets of independent variables into the regression models, best predictive 
formulas were generated for cirrhosis or marked fibrosis. Wilcoxon Mann-Whitney, χ
2
 
and Fisher's exact tests were used to compare between the variables with an SVR or 
without. The statistical analyses were made using the R program (http://www.r-
project.org) and logistic regression calculators (http://statpages.org/logistic.html). In this 
study a p-value<0.05 was considered to be statistically significant. Hardy–Weinberg 
equilibrium calculations (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) were used for IFN-λ3 
rs12979860 genotype distribution. GraphPad Prism 5 was used to create and calculate 
the receiver operating characteristics (ROC) curve and the area under the receiver oper-
ating characteristics (AUROC) parameters. The graphics were made using GraphPad 




3.1. Descriptive statistics 
A total of 116 patients chronically infected with HCV genotype 1 were included 
into this study (Table 1). All patients were treatment naïve to Peg-IFN-α and 
RBV. 48 patients were female and 68 patients were male (Figure 5) with a  medi-
an age of 51 years, and  a minimum of 22 years and a maximum of 80 years (Ta-
ble 1). The age distribution of the patients had a peak in the 6
th





 one (Figure 6) (Mechie et al. 2015). 
 




Figure 6. Age distribution of the patients included in this study on decades. 
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With regard to HCV subgenotype, 67% of the patients had the subtype 1b, 29% subtype 
1a and 4% had a coinfection with both subtypes 1a and 1b (Figure 7). 
 
Figure 7. Subgenotype distribution of HCV genotype 1 
 
The baseline median activity of AST was of 44 U/L with an IQR of 32-73 U/L. Baseline 
median ALT activity was 51 U/L with an IQR of 32-93 U/L. Both median transaminase 
activities were elevated when compared to the upper normal limits referenced by the 
UMG Diagnostic Facility Clinical Laboratory of the University Medical Center of Göt-
tingen. γ-GT had a median baseline enzymatic activity of 50 U/L with an IQR of 28-100 
U/L, which was also elevated when compared to the laboratory limits. Regarding Vita-
min B12 serum concentration the baseline median was at 488 ng/L with an IQR of 339-
727 ng/L. The median baseline level of HCV-RNA was 1.8 x 10
6





copies/ml. Patient characteristics are summarized in Table 1 





Table 1: Patient baseline characteristics 
 
A baseline histological evaluation was available for all patients. 79 patients (68%) had 
mild hepatitis activity, and 37 patients (32%) had moderate to severe hepatitis. Regard-
ing the fibrosis stage, 89 patients (77%) had absent, mild or moderate fibrosis and 27 
patients (23%) had advanced fibrosis or cirrhosis. 58 (50%) patients had no signs of he-
patic steatosis, 57 patients (49%) had hepatic steatosis, for 1 patient the hepatic steatosis 
grade was not determined in the histological evaluation (Mechie et al. 2015). 
IFN-λ3 rs12979860 genotyping showed a genotype distribution of 44:54:14 patients for 
CC:CT:TT genotypes respectively, with a minor allele frequency of 0.37 (Figure 8). 
Age [median (range)] years 51 (22-80) 







AST [median (IQR)] U/L 44 (32-73) 
ALT [median (IQR)] U/L 51 (32-93) 
-GT [median (IQR)] U/L 50 (28-100) 
Vitamin B12 [median concentration (IQR)] ng/L 488 (339-727) 






























Laboratory data are presented as median (IQR); number of cases are given in total 
and as a percentage; baseline serum Vitamin B12 concentrations were available for 
107 patients (Mechie et al. 2015). 
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The IFN-λ3 rs12979860 genotype distribution met the Hardy–Weinberg equilibrium 
with p=0.64 (Mechie et al. 2015). 
 
Figure 8. The distribution of IFN-λ3 rs12979860 genotypes 
 
3.2. Quartile of baseline serum Vitamin B12 levels with regard to treatment re-
sponse, laboratory, histological and IFN-λ3 rs12979860 genotypes  
Baseline serum Vitamin B12 levels had a median value of 488 ng/L, with an IQR of 339-
727 ng/L (Table 1). The minimum level of Vitamin B12 was 169 ng/L and the maximum 
at 2222 ng/L (Mechie et al. 2015). 
Patients who had successfully resolved chronic infection, i.e. those with a SVR, fea-
tured a lower median baseline serum Vitamin B12 concentration, 333 ng/L, than patients 
with a non-sustained virological response (NVR) with a median concentration of 616 
ng/L. The difference between Vitamin B12 serum baseline levels in responding and non-









Table 2 presents an analysis on the association between baseline serum Vitamin B12 
concentration and several clinical, laboratory, histopatological and genetic variables. 
Baseline serum Vitamin B12 concentrations were classified into quartiles. Low baseline 
serum Vitamin B12 levels were associated with achieving a RVR (p=0.001) or a SVR 
(p<0.001), lower stages of fibrosis (p=0.0001), low serum activities of AST (p=0.002) 
and ALT (p=0.04), and the favorable IFN-λ3 rs12979860 genotype CC (p=0.04). Base-
line levels of Vitamin B12 were not found to be associated with patient age, HCV sub-




Table2: Vitamin B12 quartile 




727 (n=27) P value 
Sex [female/male] n 8/19 7/20 13/13 14/13 0.29 
Age[median(range)]years 47 (23-77) 53 (22-70) 51 (32-73) 51 (23-71) 0.74 





















RVR n (%) 19 (70%) 12 (44%) 9 (35%) 5 (19%) 0.001 
SVR n (%) 22 (81%) 12 (44%) 7 (27%) 2 (7%) <0.001 
AST [median (IQR)] U/L 39 (30-54) 42 (32-51) 45 (36-77) 73 (53-121) 0.002 
ALT [median (IQR)] U/L 46 (24-94) 44 (27-64) 55 (36-85) 66 (49-150) 0.04 
γ-GT [median (IQR)] U/L 38 (28-87) 52 (24-103) 63 (41-136) 68 (28-142) 0.12 





















































IFN-λ3 rs12979860 n (%) 
       CC 
       CT 
       TT 



























Baseline serum Vitamin B12 levels and the baseline viral load were positively and sig-
nificantly correlated (p<0.0001, r=0.46) (Figure 10) (Mechie et al. 2015). 
 
Figure 10.  Spearman correlation analysis between serum baseline Vitamin B12 concentration and 
viral load (Mechie et al. 2015). 
 
3.3. Treatment response with regard to baseline serum Vitamin B12 levels, histolog-
ical features, baseline and on-treatment HCV-RNA levels and IFN-λ3 rs12979860 
genotypes 
The overall SVR rate among CHC genotype 1 patients was 41% (n=48) (Figure 11). We 
conducted a univariate analysis and found the following variables to be statistically as-
sociated with SVR: low baseline serum Vitamin B12 levels (p<0.001), RVR (p<0.001), 
low baseline viral load (p<0.001), IFN-λ3 rs12979860 CC genotype (p=0.0001), low 
stage of fibrosis (p=0.01) and low degree of steatosis (p=0.02) (Table 3). A multivariate 
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analysis revealed all these variables to be significantly and independently correlated 
with SVR (Table 3). Age and hepatitis activity were not related to treatment response 
(Mechie et al. 2015). 
 
Figure 11. SVR rate in patients with HCV genotype 1 treated with Peg-IFN-α and RBV 
Table 3: Uni- and multivariate analysis of factors associated with treatment response 




 P value P value 
Male sex n (%) 68 (59%) 0.07 0.19 
Age [median (range)] 51(22-80) 0.28  
RVR n (%) 40 (82%) <0.001 <0.001 
Vitamin B12[median (IQR)] ng/L 488 (339-727) <0.001 <0.001 
HCV RNA level [median 
(IQR)]copies/mL 
1.8x106 (4.5x105-6.2x106) <0.001 <0.05 
IFN-λ3 rs12979860 CC n (%) 28 (64%) 0.0001 <0.001 
Hepatitis activity n (%) mild 79 (68%) 0.70  
Fibrosis n (%) 
Absent/mild/moderate 
89 (77%) 0.01 <0.05 
Steatosis n (%) 
0-5% 
58 (50%) 0.02 0.01 





A cut-off value for serum Vitamin B12 of 570 ng/L was calculated using a ROC analysis 
with an AUROC of 0.83 (Std. Error 0.04, CI 0.75-9.91, p< 0.0001) (Figure 12). The 
cut-off level for serum Vitamin B12 of 570 ng/L showed a good sensitivity of 91% and 
an appropriate specificity of 58%. The positive and negative predictive values (PPV and 
NPV) were 59% and 90%, respectively (Mechie et al. 2015). 
 
Figure 12. ROC curve of baseline serum Vitamin B12 levels and relation between sensitivity and 







The patients who had baseline serum Vitamin B12 levels below the cut-off level of 570 
ng/L achieved an HCV therapy success rate of 59% and had an OR of 13.4 (CI: 4.3-
41.9, p<0.0001) in comparison to the ones with levels above this cut-off value who had 
an SVR rate of only 10% (Figure 13) (Mechie et al. 2015). 
 
Figure 13. Relation between baseline serum Vitamin B12 levels using a cut-off value of 570 ng/L and 
the SVR rates. In brackets: number of patients with SVR/total number of patients in the respective 






By combining the baseline serum Vitamin B12 570ng/L cut-off value and IFN-λ3 
rs12979860 SNP genotype, patients who had baseline serum Vitamin B12 levels below 
this cut-off value and CC genotype reached an SVR rate of 80% with an OR of 54 (CI: 
9.9-293, p<0.0001) in comparison to the ones with baseline serum Vitamin B12 above 
the cut-off level and having the CT or TT genotype (Figure 14) (Mechie et al. 2015). 
 
Figure 14. Relation between baseline serum Vitamin B12 levels using a cut-off value of 570 ng/L and 
IFN-λ3 rs12979860 genotypes with respect to SVR. In brackets are shown the number of patients 





The CHC therapy was recently revolutionized, notably due to the entrance of the new 
DAAs such as Sofosbuvir, Semiprevir, Daclatasvir, Ledipasvir, Ombitasvir, Paritaprevir 
or Dasabuvir. CHC patients who were treated with the new IFN-free regime achieve 
SVR rates above 90%-95% (Forns et al. 2014; Sulkowski et al. 2014; Afdhal et al. 
2014b). Regarding higher SVR rates for these patients, there is not necessarily a need 
for new predictors for CHC therapy. Nevertheless, the majority of CHC patients are liv-
ing in developing countries. The budget of these countries usually does not permit such 
an expensive therapy, which, from a financial aspect represents a limiting factor of the 
new CHC therapies. Considering these aspects only a fraction of the CHC patients 
would have access to a DAA-based therapy. Therefore, these patients might receive a 
CHC therapy with Peg-IFN- and RBV, which has a lower SVR rate and may generate 
serious side effects. Regarding these aspects, in order to predict the highest SVR proba-
bility, to avoid unnecessary therapy costs and side effects in the era of individualized 
medicine, more predictive factors have to be evaluated and confirmed in studies 
(Mechie et al. 2015). 
Liver fibrosis is a histopathological statement, with a huge impact on the therapy that 
requires a liver specimen, invasively obtained with a percutaneous liver puncture, lapa-
roscopy, mini-laparoscopy or transvenous liver biopsy (Denzer et al. 2007). These pro-
cedures can be associated with interventional complications such as post-interventional 
bleeding, organ perforation, pain and even death of the patients. They have also limita-
tions in patients with impaired coagulation, obesity, post-interventional peritoneal ad-
herences (Hilgard et al. 2014). Concerning these aspects the evaluation of new non-
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invasive biomarkers for liver fibrosis as well as for therapeutic outcome plays a key role 
in the therapy of patients with liver diseases.  
There are a number of demographics (black race, older age), laboratory (low λ-GT, high 
ALT activity, low λ-GT/ALT ratio, anemia under the therapy), histological stage (fibro-
sis grade, presence of steatosis hepatitis), genetical (IFN-λ3, IFN-λ4) and virological 
(genotype, baseline HCV RNA level, RVR) predictors for treatment outcome of CHC 
patients treated with a combination therapy consisting of Peg-IFN- and RBV (Kau et 
al. 2008; Ge et al. 2009; Amanzada et al. 2012a; Amanzada et al. 2013b) or with Peg-
IFN-, RBV and one of the first-generation protease inhibitors (Mechie et al. 2014). 
These factors could predict very accurately an individuals’ chance to achieve a SVR. By 
combining independent predictors, a better prediction can be achieved. One example for 
this is the combination of IFN-λ3 rs12979860 genotypes and the ratio of -GT/ALT. In 
this case, those patients with the IFN-λ3rs12979860 CC allele and low -GT/ALT quo-
tient have a 26-fold higher chance to obtain SVR under therapy with Peg-IFN- and 
RBV than patients with non-CC genotype and high -GT/ALT ratio (Mihm et al. 1999; 
Amanzada et al. 2012a). Simple and quickly measurable predictors are useful for medi-
cal doctors in countries with lower health budget to select the CHC patients who would 
achieve a high SVR rate undergoing a CHC antiviral treatment with Peg-IFN- and 
RBV (Mechie et al. 2015). 
It has been shown that in vitro conditions, Vitamin B12 binds the IRES-ribosomal struc-
ture inhibiting in a dose-dependent manner the HCV IRES-dependent translation (Lott 
et al. 2001; Li et al. 2004). On the other hand, in vivo, high levels of serum Vitamin B12 
are associated with high serum HCV RNA in CHC patients (Lott et al. 2001). Through 
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these perspectives Vitamin B12, might have opposing effects on HCV translation and 
replication.  
It has been theorized that HCV could have evolved to use high Vitamin B12 levels in the 
hepatocytes in order to obtain high replication rates, or due to the blocking activity of 
the IRES-ribosomal complex, could be one of the mechanisms through which HCV 
promotes persistence (Lott et al. 2001; Li et al. 2004; Mechie et al. 2015). 
Due to a raise in hepatic cytolysis and/or low clearance by the damaged hepatocytes a 
relative Vitamin B12 deficiency may result in some liver diseases like: hepatocellular 
carcinoma, liver metastasis, hepatitis, cirrhosis (Andres et al. 2013; Mechie et al. 2015). 
Considering these facts and with the inhibitor effect of Vitamin B12 on the HCV replica-
tion cycle (Lott et al. 2001; Li et al. 2004), it is reasonable to believe that supplementa-
tion of vitamin B12 to Peg-INF-α and RBV might improve the SVR rates in CHC pa-
tients (Rocco et al. 2013). 
Our results confirm the findings of Lott et al. regarding to a positive correlation between 
serum Vitamin B12 levels and baseline serum HCV RNA in CHC patients. We were also 
able to show that baseline serum Vitamin B12 levels were associated with the liver fi-
brosis staging in CHC-genotype-1-infected patients, making Vitamin B12 one of the 
possible non-invasive biomarkers for liver fibrosis. Regarding these results, the concen-
tration of Vitamin B12 in the hepatocytes would be interesting, and this would be proba-
bly reduced in patients with advanced liver fibrosis because of the lower number of 
hepatocytes. We also find that Vitamin B12 is inversely associated with RVR and SVR, 
a fact which could make the baseline serum Vitamin B12 in the future a simple, rapid 
measurable and affordable predictor for the therapeutic success of Peg-IFN- and RBV 
(Mechie et al. 2015). 
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In the study of Rosenberg et al. elevated serum baseline levels of Vitamin B12 were sta-
tistically associated with End-of-Treatment Response but were not correlated with SVR. 
Nevertheless, Rosenberg et al. (Rosenberg and Hagen 2011) included in their study only 
45 CHC patients infected with HCV-genotype-1. For this reason their study results may 
be statistically underpowered (Mechie et al. 2015). 
In the only prospective study until this date, Rocco et al. showed that adding Vitamin 
B12 to the classical antiviral therapy with Peg-IFN- and RBV, significantly increased 
the SVR rate in the group that received the additional Vitamin B12 as compared to the 
control group, which received only the classical antiviral therapy. The higher SVR rates 
in the patient group that received Peg-IFN-, RBV and Vitamin B12 may be due to the 
inhibition of HCV IRES-dependent translation by Vitamin B12 and by a possible direct 
interaction with the HCV IRES RNA (Lott et al. 2001; Takyar et al. 2002; Mechie et al. 
2015). On the other hand it may also be an effect of modulation that Vitamin B12 has on 
the immune system (Partearroyo et al. 2013; Mechie et al. 2015). 
In conclusion, the serum baseline Vitamin B12 concentration was significantly associat-
ed with viral load and with liver fibrosis staging in CHC patients with HCV genotype 1 
infection. Low serum vitamin B12 concentrations were found to be associated with SVR 
in a setting of a classical CHC antiviral combination therapy with Peg-IFN- and RBV, 
predicting the therapy outcome. By combining serum baseline Vitamin B12 concentra-
tion with a second predictor, i.e. IFN-λ3 rs12979860 genotype, the OR to identify the 
responding patients reaches 54. According to our results, serum Vitamin B12 concentra-
tion may be used as an affordable, rapidly determinable, noninvasive surrogate parame-
ter for liver fibrosis staging and may in addition help to predict the therapy responsive-




Chronic hepatitis C represents a worldwide health problem. In the last years new thera-
peutic strategies with a very good sustained virological response rate have been devel-
oped. These new therapeutic agents are mainly available in the economically developed 
countries. A problem in the treatment of the CHC is, globally, that the majority of pa-
tients is living in countries with health budgets unable to meet such costs. This is why 
predictors of therapeutic response under classical therapy (IFN und RBV) are still nec-
essary. In vitro studies provided evidence for Vitamin B12 to interfere with HCV replica-
tion. Thus, we retrospectively analyzed the relationship between serum baseline Vita-
min B12 concentrations and clinical data from a total of 116 CHC patients with HCV 
genotype 1 infection who received an antiviral combination therapy with Peg-IFN-α and 
RBV. The statistical approach covered uni- and multivariate analyses using logistic re-
gression models. Serum baseline Vitamin B12 concentrations were found to be positively 
associated with serum transaminase activities (AST, p=0.002, ALT, p=0.04), baseline 
viral load (p<0.0001), stage of fibrosis (p=0.0001) and the favorable IFN-λ3 
rs12979860 C allele (p=0.04). To the contrary, an inverse relationship was found be-
tween serum baseline Vitamin B12 concentrations and RVR and SVR rates (p=0.001 and 
p<0.001, respectively). By using a ROC analysis we defined a cut-off level for baseline 
serum Vitamin B12 of 570 ng/L. Patients with serum baseline Vitamin B12 concentra-
tions below this level achieved an SVR rate of 59% compared to patients with higher 
Vitamin B12 concentrations achieving an SVR rate of only 10% (OR of 13.4 (CI: 4.3-
41.9, p<0.0001). Notably, patients with serum baseline Vitamin B12 concentrations be-
low the cut-off and a favorable IFN-λ3 rs12979860 CC genotype featured SVR rates of 
80%, while patients with higher concentrations and carrying the unfavorable T allele 
reached a 7% SVR rate only (OR of 54 (CI: 9.9-293.4, p<0.0001)). Our data suggest 
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that serum baseline Vitamin B12 concentration may be used as a non-invasive marker for 
the CHC-related fibrosis. In addition, it might be taken as a useful predictor for therapy 
responsiveness by identifying patients with high chances to benefit from an antiviral 
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